Sable Mukund, Pai Trupti D, Shet Tanuja, Patil Asawari, Dhanavade Sandeep, Desai Sangeeta B
1 Tata Memorial Centre, Mumbai, India.
Int J Surg Pathol. 2017 May;25(3):230-237. doi: 10.1177/1066896916667815. Epub 2016 Sep 9.
Triple-negative breast cancers (TNBCs) are characterized by negative expression for estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors. Although the majority of basal-like breast cancers (BLBCs) diagnosed based on gene expression profiling belong to the TNBC group, both entities are not synonymous. Core BLBCs are TNBCs, which are positive for basal cytokeratin (CK) and/or epidermal growth factor receptor (EGFR). We aimed to study and correlate a TNBC cohort for various histomorphological features and immunohistochemical (IHC) profile in Indian patients. We studied 205 naïve TNBCs for histopathological features, which were further evaluated for basal CKs-namely, CK5/6, CK14, CK17-and EGFR expression to classify them as core BLBCs, using criteria of any basal CK and/or EGFR positivity and 7-negative phenotype (7NP). Among 205 TNBCs, 91% of cases were core BLBCs, and absence of ductal carcinoma in situ (DCIS) was significantly associated ( P = .014) with core BLBC. Geographic necrosis was correlated with expression of CK17 ( P = .002) and EGFR ( P = .038). A ribbon-like trabecular pattern and absence of DCIS were associated with CK17 ( P = .0002 and P = .043, respectively) and CK14 ( P = .04 and P = .0008, respectively). TNBC is a heterogeneous subgroup with adverse clinicopathological features, and many of them show significant correlation with basal CKs. TNBCs cannot be classified as core BLBC or 7NP based on morphological features, except absence of DCIS. However, this study illustrates the heterogeneity in TNBCs on the basis of IHC markers.
三阴性乳腺癌(TNBC)的特征是雌激素(ER)、孕激素(PR)和人表皮生长因子2(HER2)受体呈阴性表达。尽管基于基因表达谱诊断的大多数基底样乳腺癌(BLBC)属于TNBC组,但这两个实体并非同义词。核心BLBC是TNBC,其基底细胞角蛋白(CK)和/或表皮生长因子受体(EGFR)呈阳性。我们旨在研究印度患者TNBC队列的各种组织形态学特征和免疫组织化学(IHC)谱,并进行相关性分析。我们研究了205例初治TNBC的组织病理学特征,并进一步评估基底CKs,即CK5/6、CK14、CK17和EGFR的表达,以根据任何基底CK和/或EGFR阳性及7阴性表型(7NP)标准将它们分类为核心BLBC。在205例TNBC中,91%的病例为核心BLBC,原位导管癌(DCIS)的缺失与核心BLBC显著相关(P = 0.014)。地图状坏死与CK17(P = 0.002)和EGFR(P = 0.038)的表达相关。带状小梁模式和DCIS的缺失分别与CK17(P = 0.0002和P = 0.043)和CK14(P = 0.04和P = 0.0008)相关。TNBC是一个具有不良临床病理特征的异质性亚组,其中许多与基底CKs显示出显著相关性。除DCIS缺失外,TNBC不能根据形态学特征分类为核心BLBC或7NP。然而,本研究说明了基于IHC标志物的TNBC异质性。